Over forty different clinical trials targeting Cbl-b in a wide range of ailments, including various types of leukemia and lymphoma, adenocarcinoma, lung cancer, uveitis, and other diseases, are either in progress or have been completed in the past two decades (Supplementary Table S1), implying the potential impact of Cbl-b in this field. This evidence concerns the gene CBLB and adenocarcinoma.